Eurobio Scientific SA
PAR:ALERS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Eurobio Scientific SA
Total Receivables
Eurobio Scientific SA
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Total Receivables
€38m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
19%
|
|
|
Valneva SE
PAR:VLA
|
Total Receivables
€27.8m
|
CAGR 3-Years
5%
|
CAGR 5-Years
8%
|
CAGR 10-Years
6%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Total Receivables
€40.3m
|
CAGR 3-Years
36%
|
CAGR 5-Years
28%
|
CAGR 10-Years
21%
|
|
|
Inventiva SA
PAR:IVA
|
Total Receivables
€47.8m
|
CAGR 3-Years
65%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Total Receivables
$16.1m
|
CAGR 3-Years
13%
|
CAGR 5-Years
15%
|
CAGR 10-Years
5%
|
|
|
Abivax SA
PAR:ABVX
|
Total Receivables
€15.7m
|
CAGR 3-Years
23%
|
CAGR 5-Years
14%
|
CAGR 10-Years
15%
|
|
Eurobio Scientific SA
Glance View
Eurobio-Scientific SA engages in designing, development and commercialization of tests diagnosis in the fields of transplantation, infectious diseases, autoimmunity and oncology, as well as products for research in the field of life sciences. The company is headquartered in Les Ulis, Ile-De-France. The company went IPO on 2005-11-18. The company is engaged in activities ranging from discovery to the commercialization of specialty diagnostic products. The firm owns a portfolio of diagnostic products in three specialty areas: infectious diseases; Alzheimer's disease, and cancer. The company consists of Tetanos Quick Stick (TQS), which is an unitary test enabling to determine the tetanus vaccination status. The company has a portfolio of in-house and co-developed products, including AclarusDx (a blood-based test for the detection of biomarkers specific for Alzheimer's disease). The portfolio includes BJI Inoplex for prosthetic infections and EHT Dx14 for breast cancer (both in validation phase). The co-developed products include research programs for the identification of predictive biomarkers of response for anti-HER2 and anti-angiogenic therapies, among others. The company operates through Genbio and Eurobio Capforce Plus.
See Also
What is Eurobio Scientific SA's Total Receivables?
Total Receivables
38m
EUR
Based on the financial report for Dec 31, 2025, Eurobio Scientific SA's Total Receivables amounts to 38m EUR.
What is Eurobio Scientific SA's Total Receivables growth rate?
Total Receivables CAGR 10Y
19%
Over the last year, the Total Receivables growth was 3%. The average annual Total Receivables growth rates for Eurobio Scientific SA have been -2% over the past three years , -7% over the past five years , and 19% over the past ten years .
